Nkarta Announces September 2020 Virtual Investor Conference Schedule
September 08, 2020 16:02 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Reports Second Quarter 2020 Financial Results
August 20, 2020 16:02 ET
|
Nkarta, Inc.
Co-Lead programs on track: NKX101 expected to begin Phase 1 dosing in 4Q 2020 and IND for NKX019 expected to be filed in 1Q 2021Completed construction of cGMP clinical manufacturing facilityCompleted...
Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares
July 14, 2020 16:15 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Announces Pricing of Initial Public Offering
July 10, 2020 00:44 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...
Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at the American Association for Cancer Research (AACR) Virtual 2020 Annual Meeting II
June 22, 2020 09:52 ET
|
Nkarta
Gene editing of engineered natural killer cells contributed to enhanced cell persistence and tumor killing Combination of engineered natural killer cells and engineered T cells demonstrated potential...
Nkarta Therapeutics Appoints Two New Independent Directors
April 27, 2020 08:30 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nkarta), a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...
Nkarta Therapeutics to Present at the J.P. Morgan Healthcare Conference
January 09, 2020 08:00 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...
Nkarta Therapeutics Expands Senior Management Team with Key Hires in Finance and Clinical Development
December 09, 2019 08:00 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
Nkarta Therapeutics Presents Preclinical Data for CD19 CAR NK Program
November 18, 2019 17:16 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
Nkarta Therapeutics Named as a “Fierce 15” Biotechnology Company of 2019
September 23, 2019 09:00 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...